Freestone Grove Partners LP bought a new stake in shares of Envista Holdings Corporation (NYSE:NVST – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 28,439 shares of the company’s stock, valued at approximately $749,000.
A number of other large investors also recently added to or reduced their stakes in the business. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Envista in the 2nd quarter valued at about $25,000. Caitong International Asset Management Co. Ltd raised its stake in shares of Envista by 16,711.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock worth $31,000 after buying an additional 1,504 shares during the last quarter. Allworth Financial LP raised its stake in shares of Envista by 75.4% during the fourth quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock worth $39,000 after buying an additional 776 shares during the last quarter. UMB Bank n.a. lifted its holdings in Envista by 46.1% in the fourth quarter. UMB Bank n.a. now owns 2,017 shares of the company’s stock valued at $44,000 after buying an additional 636 shares during the period. Finally, IFP Advisors Inc lifted its holdings in Envista by 102.9% in the fourth quarter. IFP Advisors Inc now owns 2,112 shares of the company’s stock valued at $46,000 after buying an additional 1,071 shares during the period.
Envista Stock Down 1.1%
Envista stock opened at $27.15 on Friday. The company’s 50 day simple moving average is $27.12 and its 200 day simple moving average is $26.38. Envista Holdings Corporation has a fifty-two week low of $18.77 and a fifty-two week high of $30.42. The firm has a market capitalization of $4.36 billion, a price-to-earnings ratio of 46.81, a PEG ratio of 1.29 and a beta of 0.86. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.43 and a quick ratio of 2.07.
Analysts Set New Price Targets
NVST has been the subject of a number of analyst reports. Wall Street Zen raised shares of Envista from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 22nd. BMO Capital Markets assumed coverage on Envista in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $27.00 price target on the stock. Evercore reissued an “outperform” rating and issued a $33.00 price target on shares of Envista in a research note on Thursday, May 7th. Barclays reduced their price target on Envista from $34.00 to $32.00 and set an “overweight” rating on the stock in a research report on Thursday, June 11th. Finally, Zacks Research raised Envista from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $29.31.
Get Our Latest Research Report on Envista
Insider Buying and Selling at Envista
In other news, SVP Mischa Reis sold 8,000 shares of the business’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total value of $220,000.00. Following the completion of the transaction, the senior vice president owned 27,321 shares of the company’s stock, valued at $751,327.50. The trade was a 22.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.99% of the stock is currently owned by corporate insiders.
Envista Company Profile
Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.
Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.
Read More
- Five stocks we like better than Envista
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Want to see what other hedge funds are holding NVST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Envista Holdings Corporation (NYSE:NVST – Free Report).
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.
